Sobi issues 5-year SEK 600m bond

Swedish Orphan Biovitrum AB (Sobi) issues a 5-year SEK 600 million senior
unsecured bond. The bond has a floating interest of 3 months Stibor + 500 bps
with maturity in 2017.

The transaction closes ahead of the expected closing date as a result of strong
investor demand. The bond will be issued on 26 June 2012. Sobi will apply for
the loan to be listed on NASDAQ OMX Stockholm.

The bond will replace Sobi's existing term facility and will improve the
financial flexibility as well as extend the maturity profile of Sobi's debt. The
transaction was led by Nordea and SEB.



For further information, please contact:
Lars Sandström, CFO
Tel.: +46 8 697 26 33



Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 45 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 18 June 2012 at 13.00 CET.